NCT05694715 2026-03-17
Combination Therapy in Cancers With Mutations in DNA Repair Genes
University of California, San Francisco
Phase 1 Recruiting
Clinical Trials
10 trialsNCT06412120 2026-03-16
Study Evaluating Safety, Tolerability, and Metabolism of Niraparib
University of Miami
Phase 4 Recruiting
NCT01042379 2026-03-13
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2 Recruiting
NCT06915025 2026-02-27
OVATION-3
Imunon
Phase 3 Recruiting
NCT04947254 2026-02-19
Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT05601440 2026-02-11
Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer
Canadian Cancer Trials Group
Phase 2 Recruiting
NCT05718323 2026-02-06
RAISE
ETOP IBCSG Partners Foundation
Phase 2 Recruiting
NCT05700721 2026-02-05
Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06388733 2026-02-03
A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma
NeuroTrials, LLC
Phase 3 Recruiting
NCT03651206 2025-12-19
ROCSAN
ARCAGY/ GINECO GROUP
Phase 2/3 Recruiting